DIASORIN S.P.A. |
Market Closed -
Other stock markets
|
Pre-market 02:05:52 am | |||
| 89.58 EUR | 0.00% |
|
88.24 | -1.50% |
| Apr. 18 | Marshall Wace moves on Leonardo and OVS. | AN |
| Apr. 18 | More buying on stock markets; MFE good after accounts | AN |
| Sales 2024 * | 1.18B 1.26B | Sales 2025 * | 1.27B 1.35B | Capitalization | 4.78B 5.08B |
|---|---|---|---|---|---|
| Net income 2024 * | 185M 197M | Net income 2025 * | 214M 227M | EV / Sales 2024 * | 4.57 x |
| Net Debt 2024 * | 611M 649M | Net Debt 2025 * | 446M 475M | EV / Sales 2025 * | 4.11 x |
| P/E ratio 2024 * |
27.8
x | P/E ratio 2025 * |
23.5
x | Employees | 3,209 |
| Yield 2024 * |
1.05% | Yield 2025 * |
1.17% | Free-Float | 37.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on DiaSorin S.p.A.
More press releases
More news
| 1 week | +2.38% | ||
| Current month | +0.09% | ||
| 1 month | -4.17% | ||
| 3 months | +4.72% | ||
| 6 months | +7.08% | ||
| Current year | -3.93% |
1 week
86.50
91.58
1 month
82.7294.66
Current year
82.7297.50
1 year
81.24106.90
3 years
81.24208.80
5 years
81.24211.80
10 years
26.00211.80
| Managers | Title | Age | Since |
|---|---|---|---|
Carlo Rosa
CEO | Chief Executive Officer | 58 | 97-12-31 |
| Director of Finance/CFO | 53 | 10-12-31 | |
| Director/Board Member | 61 | 99-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 22-04-28 | |
Carlo Rosa
CEO | Chief Executive Officer | 58 | 97-12-31 |
| Director/Board Member | 61 | 99-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.76% | 16 M€ | -8.26% | ||
| 0.69% | 5 M€ | +12.55% | ||
| 0.17% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 89.58 | -1.08% | 187,114 |
| 24-04-17 | 90.56 | +3.66% | 376,490 |
| 24-04-16 | 87.36 | -0.21% | 120,727 |
| 24-04-15 | 87.54 | +0.97% | 93,351 |
| 24-04-12 | 86.7 | -0.91% | 114,713 |
Real-time Borsa Italiana, April 18, 2024 at 11:44 am EDT
More quotes
DiaSorin S.p.A. specializes in the development, manufacturing and marketing of in vitro diagnostic reagents. The products are used in treating infectious and viral diseases, thyroid pathologies, cancer, etc.
At the end of 2023, the group had 10 production sites located in Italy, the United States (6), Canada, Germany, and the United Kingdom.
Calendar
2024-04-23
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
89.58
EUR
Average target price
97.41
EUR
Spread / Average Target
+8.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.93% | 5.1B | |
| -1.59% | 12.47B | |
| -17.62% | 6.99B | |
| -6.68% | 4.27B | |
| +0.53% | 4.27B | |
| -48.27% | 3.45B | |
| +7.09% | 2.61B | |
| -13.71% | 2.08B | |
| -3.40% | 1.67B | |
| -12.04% | 1.48B |
- Stock Market
- Equities
- DIA Stock
